Skip to content
Use caution Drug recall · FDA · Published December 10, 2012

Upsher-Smith Recalls Divalproex Sodium Tablets Due to Label Error

Upsher-Smith recalls 11,316 bottles of Divalproex Sodium 500mg tablets because the label is missing the color-coded strength indicator.

🇺🇸 FDA recall #D-127-2013DrugUpsher-Smith Laboratories ›
Take action

Contact the company

Recalling firmUpsher Smith Laboratories, Inc.6701 Evenstad Drive · Maple Grove, MN 55369
✎ GovInfoNow plain-language explainer

Upsher-Smith Laboratories, Inc. is recalling a specific lot of Divalproex Sodium Delayed-Release Tablets, USP, 500 mg. The issue is that some bottles are missing the color-coded strength on the primary display panel of the label. This recall affects 11,316 bottles distributed nationwide and in Puerto Rico. Read more at govinfonow.com/recall/48452-upsher-smith-laboratories-inc-recalls-divalproex-sodium-delayed-release-tablets.

Source Summary by GovInfoNow · govinfonow.com/recall/48452-upsher-smith-laboratories-inc-recalls-divalproex-sodium-delayed-release-tablets · Updated October 13, 2026 · FDA enforcement record: FDA #D-127-2013

Cite this page

“Upsher-Smith Recalls Divalproex Sodium Tablets Due to Label Error.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48452-upsher-smith-laboratories-inc-recalls-divalproex-sodium-delayed-release-tablets. Based on FDA recall #D-127-2013 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-127-2013%22&limit=1).

The FDA announced on Dec. 10, 2012, that Upsher-Smith Laboratories voluntarily recalled Divalproex Sodium Delayed-Release Tablets due to labeling errors where the primary display panel lacked the color-coded strength. The agency classified the recall as Class III.

How to tell if you have it

  • Brand: Upsher-Smith Laboratories
  • Product: Divalproex Sodium Delayed-Release Tablets, USP, 500 mg Valproic Acid Activity
  • Packaging: 100-count tablets per bottle
  • NDC: 0245-0182-11
  • Lot #: 310162
  • Expiration: 09/14

The hazard

Some bottles were missing the color-coded strength on the primary display panel of the label. The recall involves 11,316 bottles distributed nationwide and in Puerto Rico.

Context

GovInfoNow's records show Upsher Smith Laboratories has had four other recalls since Nov. 20, 2012. Other recent recalls of similar products include American Regent Levocarnitine Injection Recall (April 16, 2026), Unichem Recalls Doxazosin 4mg Tablets Due to Wrong ID Imprint (Jan. 21, 2026), and American Health Packaging Buprenorphine Tablets Recall (Aug. 19, 2026).

How to tell if you have this one

Check your bottle for NDC 0245-0182-11 and Lot #310162 with an expiration date of 09/14. Verify if the primary display panel of the label is missing the color-coded strength indicator. The product contains 100-count tablets per bottle.

  • Brand
    Upsher-Smith Laboratories
  • Category
    Drug

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 11 months after the firm started it.

1. Firm started the recall: Dec 10, 201212. FDA classified it Class III: Jan 16, 201323. Published in FDA’s Enforcement Report: Jan 23, 201334. FDA terminated the recall: Nov 19, 2013420122013
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-127-2013 (December 10, 2012) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-127-2013 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA